Universidad Miguel Hernández de Elche-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2023

  1. Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects

    Pharmaceutics, Vol. 15, Núm. 7

  2. Erratum: Nanodiamonds Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases (ACS Appl. Mater. Interfaces (2022) 14:11 (13665−13677) DOI: 10.1021/acsami.2c02182)

    ACS Applied Materials and Interfaces

  3. Long-term biophysical stability of nanodiamonds combined with lipid nanocarriers for non-viral gene delivery to the retina

    International Journal of Pharmaceutics, Vol. 639

2022

  1. Nanodiamond Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases

    ACS Applied Materials and Interfaces, Vol. 14, Núm. 11, pp. 13665-13677

2021

  1. Sphingolipid extracts enhance gene delivery of cationic lipid vesicles into retina and brain

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 169, pp. 103-112

2020

  1. Brain Angiogenesis Induced by Nonviral Gene Therapy with Potential Therapeutic Benefits for Central Nervous System Diseases

    Molecular pharmaceutics, Vol. 17, Núm. 6, pp. 1848-1858

  2. Niosome-based approach for in situ gene delivery to retina and brain cortex as immune-privileged tissues

    Pharmaceutics, Vol. 12, Núm. 3

2019

  1. Cationic niosomes as non-viral vehicles for nucleic acids: Challenges and opportunities in gene delivery

    Pharmaceutics, Vol. 11, Núm. 2

  2. Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes

    Journal of Controlled Release, Vol. 304, pp. 181-190

  3. Non-viral vectors based on cationic niosomes and minicircle DNA technology enhance gene delivery efficiency for biomedical applications in retinal disorders

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 308-318

2018

  1. Gene transfer to rat cerebral cortex mediated by polysorbate 80 and poloxamer 188 nonionic surfactant vesicles

    Drug Design, Development and Therapy, Vol. 12, pp. 3937-3949

  2. Non-viral vectors based on cationic niosomes as efficient gene delivery vehicles to central nervous system cells into the brain

    International Journal of Pharmaceutics, Vol. 552, Núm. 1-2, pp. 48-55

  3. Polysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administration

    International Journal of Pharmaceutics, Vol. 550, Núm. 1-2, pp. 388-397

2017

  1. Non-viral vectors based on magnetoplexes, lipoplexes and polyplexes for VEGF gene delivery into central nervous system cells

    International Journal of Pharmaceutics, Vol. 521, Núm. 1-2, pp. 130-140

  2. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60

    Journal of Controlled Release, Vol. 254, pp. 55-64

2016

  1. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain

    Biomaterials, Vol. 77, pp. 267-279

2015

  1. Niosomes based on synthetic cationic lipids for gene delivery: The influence of polar head-groups on the transfection efficiency in HEK-293, ARPE-19 and MSC-D1 cells

    Organic and Biomolecular Chemistry, Vol. 13, Núm. 4, pp. 1068-1081

  2. Protamine/DNA/niosome ternary nonviral vectors for gene delivery to the retina: The role of protamine

    Molecular Pharmaceutics, Vol. 12, Núm. 10, pp. 3658-3671

2014

  1. A novel cationic niosome formulation for gene delivery to the retina

    Journal of Controlled Release, Vol. 174, Núm. 1, pp. 27-36

2013

  1. Low molecular weight oligochitosans for non-viral retinal gene therapy

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 83, Núm. 2, pp. 131-140